首页> 外文OA文献 >POS1027 EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

【2h】

POS1027 EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

机译：POS1027 Guselkumab的疗效和安全性，一种特异于白细胞介素-23的P19-亚基的单克隆抗体，通过2年：在生物学 - 诺威患者中进行的第3期，随机，双盲，安慰剂对照研究的活性银屑病关节炎

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
I. Mcinnes; P. Rahman; A. B. Gottlieb; E. C. Hsia; A. Kollmeier; X. L. Xu; S. Sheng; Y. Jiang; M. Shawi; S. D. Chakravarty; D. Van der Heijde; P. J. Mease;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study [J] . Deodhar Atul, Gottlieb Alice B., Boehncke Wolf-Henning, The Lancet . 2018,第10136期

机译：Guselkumab在活性银屑病关节炎患者中的疗效和安全性：随机，双盲，安慰剂控制，第2期研究
2. Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing. [J] . McInnes Iain B., Mease Philip J., Kirkham Bruce, Arthritis & rheumatology. . 2014,第12期

机译：Secukinumab是一种人类抗白介素17A单克隆抗体，可改善活动型银屑病关节炎：使用皮下给药的一项3期随机，多中心，双盲，安慰剂对照研究的24周疗效和安全性数据。
3. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial [J] . RitchlinC., RahmanP., KavanaughA., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第6期

机译：抗IL-12/23 p40单克隆抗体，Ustekinumab，在患有常规非生物和生物抗肿瘤坏死因子治疗的患者中，抗IL-12/23 p40单克隆抗体，Ustekinumab的功效和安全性：6个月和1年的第3阶段结果，多中心，双盲，安放的，随机的psummit 2试验
4. A Randomized, Placebo-Controlled Study of the Efficacy of Cognitive Intervention on Elderly People and on Patient's with Alzheimer's Disease [C] . J.J. Yanguas, C. Buiza, I. Etxeberria, International Conference on Computers Helping People with Special Needs(ICCHP 2006); 20060711-13; Linz(AT) . 2006

机译：认知干预对老年人和阿尔茨海默氏病患者疗效的随机，安慰剂对照研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Extended report: Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody ustekinumab in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3 multicentre double-blind placebo-controlled randomised PSUMMIT 2 trial [O] . Christopher Ritchlin, Proton Rahman, Arthur Kavanaugh, -1

机译：扩展报告：抗IL-12 / 23 p40单克隆抗体ustekinumab在活动性银屑病关节炎患者中的疗效和安全性尽管采用传统的非生物和生物抗肿瘤坏死因子疗法：6个月和1年的结果3期多中心双盲安慰剂对照随机PSUMMIT 2试验
7. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial [O] . Ritchlin, C., Rahman, P., Kavanaugh, A., 2014

机译：尽管常规的非生物和生物抗肿瘤坏死因子治疗，抗IL-12/23 p40单克隆抗体ustekinumab在活动性银屑病关节炎患者中的疗效和安全性：第3阶段的6个月和1年结果，多中心，双盲，安慰剂对照，随机psUmmIT 2试验

POS1027 EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

著录项

引文网络

相似文献

相关主题

期刊订阅